JP2010516758A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010516758A5 JP2010516758A5 JP2009547177A JP2009547177A JP2010516758A5 JP 2010516758 A5 JP2010516758 A5 JP 2010516758A5 JP 2009547177 A JP2009547177 A JP 2009547177A JP 2009547177 A JP2009547177 A JP 2009547177A JP 2010516758 A5 JP2010516758 A5 JP 2010516758A5
- Authority
- JP
- Japan
- Prior art keywords
- mtd
- peptide
- protein
- group
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 description 37
- 230000000975 bioactive effect Effects 0.000 description 14
- 108090000623 proteins and genes Proteins 0.000 description 14
- 102000004169 proteins and genes Human genes 0.000 description 14
- 238000000034 method Methods 0.000 description 13
- 125000003275 alpha amino acid group Chemical group 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 12
- 230000026683 transduction Effects 0.000 description 11
- 238000010361 transduction Methods 0.000 description 11
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 10
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 10
- 230000002209 hydrophobic effect Effects 0.000 description 10
- 102000004196 processed proteins & peptides Human genes 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 5
- 238000003752 polymerase chain reaction Methods 0.000 description 4
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108010070875 Human Immunodeficiency Virus tat Gene Products Proteins 0.000 description 2
- -1 antibodies Proteins 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 102000029797 Prion Human genes 0.000 description 1
- 108091000054 Prion Proteins 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 238000004163 cytometry Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 108091005573 modified proteins Proteins 0.000 description 1
- 102000035118 modified proteins Human genes 0.000 description 1
- 230000007659 motor function Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000031787 nutrient reservoir activity Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 238000009163 protein therapy Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Images
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US88706007P | 2007-01-29 | 2007-01-29 | |
| US60/887,060 | 2007-01-29 | ||
| PCT/KR2008/000525 WO2008093982A1 (en) | 2007-01-29 | 2008-01-29 | Novel macromolecule transduction domains and methods for identification and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013207349A Division JP2014057586A (ja) | 2007-01-29 | 2013-10-02 | 巨大分子伝達ドメインならびにその同定方法および使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010516758A JP2010516758A (ja) | 2010-05-20 |
| JP2010516758A5 true JP2010516758A5 (enExample) | 2011-04-21 |
| JP5518488B2 JP5518488B2 (ja) | 2014-06-11 |
Family
ID=39674245
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009547177A Active JP5518488B2 (ja) | 2007-01-29 | 2008-01-29 | 巨大分子伝達ドメインならびにその同定方法および使用 |
| JP2013207349A Pending JP2014057586A (ja) | 2007-01-29 | 2013-10-02 | 巨大分子伝達ドメインならびにその同定方法および使用 |
| JP2015090144A Active JP6140759B2 (ja) | 2007-01-29 | 2015-04-27 | 巨大分子伝達ドメインならびにその同定方法および使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013207349A Pending JP2014057586A (ja) | 2007-01-29 | 2013-10-02 | 巨大分子伝達ドメインならびにその同定方法および使用 |
| JP2015090144A Active JP6140759B2 (ja) | 2007-01-29 | 2015-04-27 | 巨大分子伝達ドメインならびにその同定方法および使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US8629097B2 (enExample) |
| EP (2) | EP2837636B1 (enExample) |
| JP (3) | JP5518488B2 (enExample) |
| KR (18) | KR20090103957A (enExample) |
| CN (1) | CN101616928B (enExample) |
| AU (1) | AU2008211854C1 (enExample) |
| CA (1) | CA2676797C (enExample) |
| WO (1) | WO2008093982A1 (enExample) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2438962A3 (en) | 2006-02-13 | 2012-07-18 | Alethia Biotherapeutics Inc. | Polynucleotides and polypeptide sequences involved in the process of bone remodeling |
| US8168181B2 (en) | 2006-02-13 | 2012-05-01 | Alethia Biotherapeutics, Inc. | Methods of impairing osteoclast differentiation using antibodies that bind siglec-15 |
| WO2008105630A1 (en) | 2007-02-27 | 2008-09-04 | Procell Therapeutics Inc. | Combined use of cell permeable nanog and oct4 for increasing self-renewal and suppressing differentiation of stem cells |
| US8450279B2 (en) | 2007-09-04 | 2013-05-28 | Procell Therapeutics Inc. | Cell permeable Nm23 recombinant proteins, polynucleotides encoding the same, and anti-metastatic composition comprising the same |
| KR100887266B1 (ko) * | 2007-09-04 | 2009-03-06 | 주식회사 프로셀제약 | 세포투과성 ｐ１８ 재조합 단백질, 이를 코딩하는폴리뉴클레오티드 및 이를 유효성분으로 함유하는 항암조성물 |
| WO2009061130A2 (en) * | 2007-11-06 | 2009-05-14 | Procell Therapeutics Inc. | Cell permeable runx3 recombinant proteins, polynucleotides encoding the same, and anticancer compositions including the same |
| US8586544B2 (en) * | 2008-04-04 | 2013-11-19 | Procell Therapeutics Inc. | Cell-permeable endostatin recombinant protein, a polynucleotide encoding the same, and an anti-cancer preparation containing the same as an active component |
| EP2407488A4 (en) * | 2009-03-12 | 2013-03-13 | Procell Therapeutics Inc | DETERMINATION OF INDUCED PLURIPOTENT STEM CELLS BASED ON A CELL PERMEABLIC REPOGRAMMING TRANSCRIPTION FACTOR FOR PERSONALIZED STEM CELL THERAPY |
| DK3252068T3 (da) | 2009-10-12 | 2025-08-25 | Larry J Smith | Metoder og sammensætninger til modulering af genekspression ved anvendelse af oligonukleotidbaserede lægemidler administreret in vivo eller in vitro |
| TW201302800A (zh) * | 2011-06-10 | 2013-01-16 | Oncotherapy Science Inc | Ｓｅｍａ５ｂ胜肽及含其之疫苗 |
| US8859507B2 (en) | 2011-08-16 | 2014-10-14 | Samsung Electronics Co., Ltd. | Protein complex for intracellular delivery and uses thereof |
| JP6001082B2 (ja) * | 2011-11-23 | 2016-10-05 | プロセル セラピューティックス インコーポレーティッド | 細胞透過能を改善した改良形の新規巨大分子伝達ドメインの開発及びその利用方法 |
| WO2013077681A1 (ko) * | 2011-11-23 | 2013-05-30 | 주식회사 프로셀제약 | 세포내 분자 전송 펩티드를 이용한 피부 생리 활성 분자의 경피 전달시스템 |
| KR101258279B1 (ko) * | 2011-11-23 | 2013-04-25 | 주식회사 프로셀제약 | 세포 투과능을 개선한 개량형 신규 거대 분자 전달 도메인 개발 및 이의 이용방법 |
| CN104661672B (zh) | 2012-05-11 | 2017-03-08 | 珍白斯凯尔有限公司 | 用于预防或治疗败血症的组合物 |
| ES2691070T3 (es) | 2012-05-11 | 2018-11-23 | Kael-Gemvax Co.,Ltd | Péptidos antiinflamatorios y composición que comprende los mismos |
| WO2014005219A1 (en) * | 2012-07-02 | 2014-01-09 | Iprogen Biotech Inc. | Intracellular protein delivery |
| ES2981865T3 (es) | 2012-07-11 | 2024-10-10 | Gemvax & Kael Co Ltd | Conjugado que comprende un péptido de penetración celular y composiciones que comprenden el mismo |
| IN2014KN02933A (enExample) | 2012-07-19 | 2015-05-08 | Alethia Biotherapeutics Inc | |
| ES2758451T3 (es) * | 2012-09-19 | 2020-05-05 | Gemvax & Kael Co Ltd | Péptido de penetración celular, conjugado que comprende el mismo y composición que comprende el conjugado |
| US9631184B2 (en) | 2012-09-19 | 2017-04-25 | Gemvax & Kael Co., Ltd. | Cell penetrating peptide, conjugate comprising same, and composition comprising conjugate |
| EP2987497B1 (en) | 2013-04-19 | 2018-12-26 | Gemvax & Kael Co., Ltd. | Composition for treating and preventing ischemic damage |
| AU2014275610B2 (en) | 2013-06-07 | 2018-06-14 | Gemvax & Kael Co., Ltd. | Biological markers useful in cancer immunotherapy |
| JP6495899B2 (ja) | 2013-06-21 | 2019-04-03 | ジェムバックス アンド カエル カンパニー，リミティド | ホルモン分泌調節剤、及びそれを含む組成物 |
| GB201315321D0 (en) | 2013-08-28 | 2013-10-09 | Koninklijke Nederlandse Akademie Van Wetenschappen | Transduction Buffer |
| KR101691479B1 (ko) | 2013-10-23 | 2017-01-02 | 주식회사 젬백스앤카엘 | 전립선 비대증 치료 및 예방용 조성물 |
| KR102694658B1 (ko) | 2013-11-22 | 2024-08-14 | 주식회사 젬백스앤카엘 | 혈관 신생 억제 활성을 가지는 펩티드 및 이를 포함하는 조성물 |
| JP6367950B2 (ja) | 2013-12-17 | 2018-08-01 | ジェムバックス アンド カエル カンパニー，リミティド | 前立腺癌治療用組成物 |
| WO2015123750A1 (en) | 2014-02-20 | 2015-08-27 | Cura Health Inc. | Transdermal composition for treating pain |
| US9937240B2 (en) | 2014-04-11 | 2018-04-10 | Gemvax & Kael Co., Ltd. | Peptide having fibrosis inhibitory activity and composition containing same |
| ES2962532T3 (es) | 2014-04-30 | 2024-03-19 | Gemvax & Kael Co Ltd | Composición para el trasplante de órganos, tejidos o células, kit y procedimiento de trasplante |
| WO2015183044A1 (ko) * | 2014-05-29 | 2015-12-03 | 주식회사 프로셀테라퓨틱스 | 신규한 세포투과성 펩타이드 및 이와 보툴리눔 독소 결합체 및 이들의 용도 |
| WO2016028036A1 (en) | 2014-08-17 | 2016-02-25 | Cellivery Therapeutics, Inc. | Advanced macromolecule transduction domain (amtd) sequences for improvement of cell-permeability, polynucleotides encoding the same, method to identify the unique features of amtds comprising the same, method to develop the amtd sequences comprising the same |
| US20160060311A1 (en) * | 2014-08-27 | 2016-03-03 | Daewoong Jo | Development of Protein-Based Biotherapeutics That Penetrates Cell-Membrane and Induces Anti-Lung Cancer Effect - Improved Cell-Permeable Suppressor of Cytokine Signaling (iCP-SOCS3) Proteins, Polynucleotides Encoding the Same, and Anti-Lung Cancer Compositions Comprising the Same |
| CN104548073B (zh) * | 2014-12-12 | 2017-08-11 | 浙江大学 | Prx I重组蛋白在制备抗细菌性败血症药物中的应用 |
| US20170369529A1 (en) * | 2014-12-22 | 2017-12-28 | Hoffmann-La Roche Inc. | Cell penetrating peptides |
| KR102413243B1 (ko) | 2014-12-23 | 2022-06-27 | 주식회사 젬백스앤카엘 | 안질환 치료 펩티드 및 이를 포함하는 안질환 치료용 조성물 |
| JP6751097B2 (ja) | 2015-02-27 | 2020-09-02 | ジェムバックス アンド カエル カンパニー，リミティド | 聴力損傷予防用ペプチド及びそれを含む組成物 |
| KR20250073577A (ko) | 2015-05-26 | 2025-05-27 | 주식회사 젬백스앤카엘 | 신규 펩티드 및 이를 포함한 조성물 |
| KR102638286B1 (ko) | 2015-07-02 | 2024-02-20 | 주식회사 젬백스앤카엘 | 항바이러스 활성 효능을 가지는 펩티드 및 이를 포함하는 조성물 |
| US20170029798A1 (en) * | 2015-07-27 | 2017-02-02 | Cellivery Therapeutics, Inc. | Development of Improved Cell-Permeable (iCP) Parkin Recombinant Protein as a Protein-Based Anti-Neurodegenerative Agent for the Treatment of Parkinson's Disease-Associated Phenotypes by Utilizing BBB-Penetrating Protein Delivery System MITT, Enabled by Advanced Macromolecule Transduction Domain (aMTD) |
| WO2017026776A1 (en) * | 2015-08-10 | 2017-02-16 | Cellivery Therapeutics, Inc. | Improved cell-permeable reprogramming factor (icp-rf) recombinant protein and use thereof |
| EP3334756B1 (en) | 2015-08-10 | 2020-06-17 | Cellivery Therapeutics, Inc. | Improved cell-permeable cre (icp-cre) recombinant protein and use thereof |
| EP3337815B1 (en) | 2015-08-18 | 2020-12-16 | Cellivery Therapeutics, Inc. | Cell-permeable (cp)- socs3 recombinant protein and uses thereof |
| GB201521101D0 (en) | 2015-11-30 | 2016-01-13 | Koninklijke Nederlandse Akademie Van Wetenschappen | Transduction buffer |
| KR101800407B1 (ko) * | 2016-04-04 | 2017-11-22 | 건국대학교 산학협력단 | 비단뱀으로부터 분리한 신규한 항균 펩타이드 및 이의 발굴 방법 |
| CN109328068A (zh) | 2016-04-07 | 2019-02-12 | 珍白斯凯尔有限公司 | 具有增加端粒酶活性和延长端粒的效果的肽以及包含该肽的组合物 |
| WO2018068135A1 (en) * | 2016-10-12 | 2018-04-19 | Feldan Bio Inc. | Rationally-designed synthetic peptide shuttle agents for delivering polypeptide cargos from an extracellular space to the cytosol and/or nucleus of a target eukaryotic cell, uses thereof, methods and kits relating to same |
| JP7062595B2 (ja) * | 2016-10-23 | 2022-05-06 | デンカ株式会社 | 複合ポリペプチド単量体、細胞浸透機能を有する当該複合ポリペプチドの単量体の会合体、及び、当該会合体を有効成分とする皮下、皮内、経皮又は筋肉内投与用ノロウイルスコンポーネントワクチン |
| CN106995487B (zh) * | 2017-04-17 | 2019-12-03 | 扬州大学 | 源于鸡传染性贫血病毒VP1-aa 23-43多肽作为高效细胞穿膜肽的应用 |
| CN106831957B (zh) * | 2017-04-17 | 2019-12-03 | 扬州大学 | 一种源于鸡传染性贫血病毒VP1-aa 1-19多肽作为高效细胞穿膜肽的应用 |
| WO2019108047A2 (ko) | 2017-12-01 | 2019-06-06 | 주식회사 굳티셀 | 탈모의 예방 또는 치료용 조성물 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1031959C (zh) * | 1991-04-11 | 1996-06-05 | 住友电气工业株式会社 | 测量涂层状态的方法和设备 |
| US5807746A (en) * | 1994-06-13 | 1998-09-15 | Vanderbilt University | Method for importing biologically active molecules into cells |
| US6248558B1 (en) | 1998-03-31 | 2001-06-19 | Vanderbilt University | Sequence and method for genetic engineering of proteins with cell membrane translocating activity |
| US20030077289A1 (en) * | 2001-02-15 | 2003-04-24 | Rong-Fu Wang | Use of cell-penetrating peptides to generate antitumor immunity |
| AU2003218815A1 (en) | 2002-03-29 | 2003-12-02 | Creagene Inc. | Cytoplasmic transduction peptides and uses thereof |
| US6835810B2 (en) | 2002-05-13 | 2004-12-28 | Geneshuttle Biopharma, Inc. | Fusion protein for use as vector |
| SE0201863D0 (en) * | 2002-06-18 | 2002-06-18 | Cepep Ab | Cell penetrating peptides |
| US20070154437A1 (en) | 2002-09-03 | 2007-07-05 | Pingfan Rao | Peptide-tagged proteins and methods of making and using thereof |
| US20040043463A1 (en) * | 2002-09-03 | 2004-03-04 | Pingfan Rao | Peptide-tagged proteins and compositions for regulating features of the skin or hair; methods of making, and methods of using thereof |
| US7166692B2 (en) * | 2003-03-04 | 2007-01-23 | Canbrex Bio Science Walkersville, Inc. | Intracellular delivery of small molecules, proteins, and nucleic acids |
-
2008
- 2008-01-29 KR KR1020097017564A patent/KR20090103957A/ko not_active Ceased
- 2008-01-29 WO PCT/KR2008/000525 patent/WO2008093982A1/en not_active Ceased
- 2008-01-29 CA CA2676797A patent/CA2676797C/en active Active
- 2008-01-29 US US12/524,935 patent/US8629097B2/en active Active
- 2008-01-29 CN CN200880003468.9A patent/CN101616928B/zh active Active
- 2008-01-29 JP JP2009547177A patent/JP5518488B2/ja active Active
- 2008-01-29 AU AU2008211854A patent/AU2008211854C1/en active Active
- 2008-01-29 EP EP14184544.6A patent/EP2837636B1/en active Active
- 2008-01-29 EP EP08712219A patent/EP2129682A4/en not_active Withdrawn
-
2013
- 2013-10-02 JP JP2013207349A patent/JP2014057586A/ja active Pending
- 2013-11-27 US US14/091,823 patent/US9040477B2/en active Active
-
2015
- 2015-04-27 JP JP2015090144A patent/JP6140759B2/ja active Active
-
2016
- 2016-03-31 KR KR1020160039707A patent/KR102217269B1/ko active Active
-
2020
- 2020-02-28 KR KR1020200025231A patent/KR102217321B1/ko active Active
- 2020-02-28 KR KR1020200025224A patent/KR102217299B1/ko active Active
- 2020-02-28 KR KR1020200025220A patent/KR102217274B1/ko active Active
- 2020-02-28 KR KR1020200025230A patent/KR102217320B1/ko active Active
- 2020-02-28 KR KR1020200025229A patent/KR102217317B1/ko active Active
- 2020-02-28 KR KR1020200025226A patent/KR102217308B1/ko active Active
- 2020-02-28 KR KR1020200025225A patent/KR102217304B1/ko active Active
- 2020-02-28 KR KR1020200025232A patent/KR102217324B1/ko active Active
- 2020-02-28 KR KR1020200025234A patent/KR102217331B1/ko active Active
- 2020-02-28 KR KR1020200025235A patent/KR102254723B1/ko active Active
- 2020-02-28 KR KR1020200025223A patent/KR102217295B1/ko active Active
- 2020-02-28 KR KR1020200025227A patent/KR102217310B1/ko active Active
- 2020-02-28 KR KR1020200025222A patent/KR102217281B1/ko active Active
- 2020-02-28 KR KR1020200025233A patent/KR102217325B1/ko active Active
- 2020-02-28 KR KR1020200025228A patent/KR102217313B1/ko active Active
- 2020-02-28 KR KR1020200025221A patent/KR102217277B1/ko active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010516758A5 (enExample) | ||
| KR100981356B1 (ko) | 신호서열 및 변이된 신호서열로 디자인된 분비증강자에의한 원래 형태의 수용성 재조합 단백질 생산 방법 | |
| CN110511280B (zh) | 一种透皮重组纤连蛋白及其应用 | |
| EP2351775B1 (en) | Fusion protein comprising ubiquitin or ubiquitin-like protein, membrane translocation sequence and biologically active molecule and use thereof | |
| US8859507B2 (en) | Protein complex for intracellular delivery and uses thereof | |
| US20180016310A1 (en) | Fusion proteins of superfolder green fluorescent protein and use thereof | |
| WO2014165093A2 (en) | Fibronectin based scaffold domains linked to serum albumin or a moiety binding thereto | |
| JP2007508846A5 (enExample) | ||
| CN101134780A (zh) | 阻断nr2b信号通路的多肽类似物及其制备方法和药物用途 | |
| CN107698684A (zh) | 包含突变的免疫球蛋白Fc部分的GLP‑1融合蛋白 | |
| JPH0797995B2 (ja) | ペプチド類の製造法 | |
| WO2022241831A1 (zh) | 多肽的制备方法 | |
| CN101240033A (zh) | 一种促胰岛素分泌肽与人血清白蛋白的融合蛋白及其制备方法 | |
| CN101343327A (zh) | 一种抗病毒蛋白质及其应用 | |
| CN111388680B (zh) | 一种多肽复合物作为多肽或蛋白质药物载体的应用、方法及其融合蛋白复合物 | |
| US20190352365A1 (en) | Expression construct and method for producing proteins of interest | |
| CN109776653B (zh) | 一种人血清白蛋白黏附肽及其应用 | |
| CN102174110B (zh) | 狂犬病毒糖蛋白衍生肽及其应用 | |
| CN102993309B (zh) | 一种人生长素融合蛋白TAT-hGH及其制备方法和应用 | |
| CN111448320B (zh) | 细胞膜穿透肽 | |
| CN101389649A (zh) | 多肽拮抗剂 | |
| WO2022192687A1 (en) | Synthetic promoters for gene therapy and protein expression | |
| KR20220117091A (ko) | 생체내 세포에서 합성 및 분비되고 세포로 투과하는 관심 폴리펩타이드를 코딩하는 발현카세트 및 이의 용도 | |
| JP2022548598A (ja) | 組換え治療用ペプチドの発現のためのｎ末端伸長配列 | |
| US20240166696A1 (en) | Scaffolds For Inducing Antibody Responses Against Antigenic Sites |